Individuals with a personal or family history of Medullary Thyroid Carcinoma - Semaglutide can increase the risk of developing this type of cancer.
Those who have experienced pancreatitis - Individuals with a history of pancreatitis or who have developed pancreatitis while on other GLP-1 receptor agonists should avoid Semaglutide, as it may increase the risk of recurrence.
Patients with a history of gallbladder disease - Semaglutide can impact gallbladder function.
Pregnant or breastfeeding women - The effects of Semaglutide on pregnancy and breastfeeding are not fully known.
People with “normal” weight - Semaglutide is intended for chronic weight management in people who are obese or overweight with at least one weight-related condition. It is not recommended for cosmetic weight loss or for individuals who are not significantly overweight.